NCT06883214 Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
| NCT ID | NCT06883214 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Regina Elena Cancer Institute |
| Condition | Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-01-17 |
| Primary Completion | 2027-01-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2023-01-17 with a primary completion date of 2027-01-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.
Eligibility Criteria
Inclusion Criteria: * histological diagnosis of glioma; * no concomitant primary tumor; * no metastatic disease; * availability of surgical material/tissue; * written informed consent. Exclusion Criteria: * histological diagnosis of non-glial tumor; * patients with concomitant other solid tumors; * metastatic disease; * no surgical material/tissue available; * HIV seropositivity.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06883214 clinical trial?
This trial is open to participants of all sexes, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06883214 currently recruiting?
Yes, NCT06883214 is actively recruiting participants. Contact the research team at anabelen.diaz@ifo.it for enrollment information.
Where is the NCT06883214 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06883214 clinical trial?
NCT06883214 is sponsored by Regina Elena Cancer Institute. The trial plans to enroll 10 participants.